Indications
Intraocular injections are the fastest growing procedure in ophthalmology. They are commonly used for the treatment age-related macular degeneration (bevacizumab, ranibizumab), iris neovascularization secondary to proliferative diabetic retinopathy (bevacizumab), and macular edema (bevacizumab and triamcinolone acetonide) due to diabetic retinopathy, vein occlusion, or uveitis.
In addition intravitreal methotrexate has been used to treat intraocular lymphoma associated with primary central nervous system lymphoma. Less commonly it has been used in patients with uveitis and advanced proliferative diabetic retinopathy.
Adverse Effects
Intravitreal injections often lead to increased intraocular pressure (IOP) immediately after the procedure. In 2008, Kim et al. demonstrated that eyes injected with ranibizumab, bevacizumab, pegaptanib, and triamcinolone acetonide had transient IOP spikes immediately after the procedure. However, close monitoring is necessary especially in...
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Wayman, L.L. (2012). Intraocular Injection of Ocular Drugs. In: Schmidt-Erfurth, U., Kohnen, T. (eds) Encyclopedia of Ophthalmology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-35951-4_81-2
Download citation
DOI: https://doi.org/10.1007/978-3-642-35951-4_81-2
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Online ISBN: 978-3-642-35951-4
eBook Packages: Springer Reference MedicineReference Module Medicine